EA201070730A1 - Гуманизированные антитела, специфичные к фактору фон виллебранда - Google Patents

Гуманизированные антитела, специфичные к фактору фон виллебранда

Info

Publication number
EA201070730A1
EA201070730A1 EA201070730A EA201070730A EA201070730A1 EA 201070730 A1 EA201070730 A1 EA 201070730A1 EA 201070730 A EA201070730 A EA 201070730A EA 201070730 A EA201070730 A EA 201070730A EA 201070730 A1 EA201070730 A1 EA 201070730A1
Authority
EA
Eurasian Patent Office
Prior art keywords
humanized antibodies
antibodies specific
villebrand
von factor
factor
Prior art date
Application number
EA201070730A
Other languages
English (en)
Inventor
Элиас Лазаридс
Кэтрин Вудс
Сяомин Фэн
Самюэль Хоу
Харальд Моттл
Станислас Блейн
Мартин Бертшингер
Original Assignee
Гленмарк Фармасьютикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40613108&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201070730(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Гленмарк Фармасьютикалс С.А. filed Critical Гленмарк Фармасьютикалс С.А.
Publication of EA201070730A1 publication Critical patent/EA201070730A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Настоящее описание относится к гуманизированным антителам, специфичным к фактору фон Виллебранда (vWF) человека или связывающим фрагментам указанных антител, способам их получения и применения, включая способы лечения опосредованных vWF заболеваний или расстройств.
EA201070730A 2008-01-23 2009-01-22 Гуманизированные антитела, специфичные к фактору фон виллебранда EA201070730A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2302508P 2008-01-23 2008-01-23
US4478708P 2008-04-14 2008-04-14
PCT/IB2009/000124 WO2009093138A1 (en) 2008-01-23 2009-01-22 Humanized antibodies specific for von willebrand factor

Publications (1)

Publication Number Publication Date
EA201070730A1 true EA201070730A1 (ru) 2011-04-29

Family

ID=40613108

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070730A EA201070730A1 (ru) 2008-01-23 2009-01-22 Гуманизированные антитела, специфичные к фактору фон виллебранда

Country Status (21)

Country Link
US (1) US8236315B2 (ru)
EP (1) EP2245069B1 (ru)
JP (1) JP2011510622A (ru)
KR (1) KR20100113589A (ru)
CN (1) CN101932606A (ru)
AP (1) AP2010005332A0 (ru)
AR (1) AR070141A1 (ru)
AU (1) AU2009207340A1 (ru)
BR (1) BRPI0905761A2 (ru)
CA (1) CA2712221A1 (ru)
CL (1) CL2009000123A1 (ru)
CO (1) CO6280500A2 (ru)
DK (1) DK2245069T3 (ru)
EA (1) EA201070730A1 (ru)
ES (1) ES2495092T3 (ru)
IL (1) IL207134A0 (ru)
MX (1) MX2010008060A (ru)
PE (1) PE20091351A1 (ru)
TW (1) TW200938630A (ru)
WO (1) WO2009093138A1 (ru)
ZA (1) ZA201005373B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079944A1 (es) * 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
US20150183885A1 (en) * 2012-06-08 2015-07-02 Glenmark Pharmaceuticals S.A. Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
AU2014302016B2 (en) * 2013-06-26 2017-08-31 Mohammed ELASHWAH System and method for detecting prescription, transcription and administration errors in drug administration
CN103760358A (zh) * 2013-11-12 2014-04-30 赵铁铭 一种用于检测冯维勒布兰德因子的试剂及其制备方法和应用
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
KR20160131082A (ko) * 2014-03-12 2016-11-15 프로테나 바이오사이언시즈 리미티드 Lg1-3에 특이적인 항-라미닌4 항체
WO2015136469A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EP3116907A1 (en) 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
CN106659771B (zh) * 2014-07-02 2021-09-24 康诺贝林伦瑙有限公司 修饰的von Willebrand因子
JP2018524284A (ja) * 2015-05-18 2018-08-30 ユーリカ セラピューティックス， インコーポレイテッド 抗ｒｏｒ１抗体
US11107566B2 (en) * 2016-09-30 2021-08-31 Novo Nordisk A/S Systems and methods for communicating a dose history representing an average and a variability of a distribution of medicament injections
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11576840B1 (en) * 2019-04-26 2023-02-14 INMAR Rx SOLUTIONS, INC. Medication inventory system including RFID based medication discrepancy determination and related methods
GB202105625D0 (en) * 2021-04-20 2021-06-02 Ip2Ipo Innovations Ltd Von willebrand factor (VWF) inhibitors

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) * 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) * 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) * 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) * 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) * 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) * 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) * 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
ATE186219T1 (de) 1993-03-24 1999-11-15 Berlex Biosciences Kombination von antihormonale und bindende moleküle zur krebsbehandlung
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
DE69530316T2 (de) * 1994-11-30 2004-02-12 Ajinomoto Co., Inc. Antithrombose mittel und gegen den von willebrand-faktor gerichtete monoklonale antikörper
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JPH11510170A (ja) 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド タンパク質の処方
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
JP2002529373A (ja) * 1998-10-23 2002-09-10 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド コンホメーション特異的抗ｖｏｎＷｉｌｌｅｂｒａｎｄ因子抗体
CA2441937A1 (en) * 2001-05-30 2002-12-05 Chromos Molecular Systems, Inc. Chromosome-based platforms
WO2004006955A1 (en) * 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US7786264B2 (en) * 2001-11-08 2010-08-31 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof
CA2522067C (en) * 2003-04-09 2010-07-06 Canadian Blood Services Detection, characterization and treatment of viral infection and methods thereof
WO2005035577A1 (ja) * 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. ガングリオシドｇｄ３に特異的に結合する抗体組成物
WO2006046935A1 (en) * 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc Methods of optimizing antibody variable region binding affinity
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
FR2889534B1 (fr) * 2005-08-04 2012-11-02 Lab Francais Du Fractionnement Anticorps anti-idiotypique neutralisant l'activite inhibitrice d'un anticorps inhibiteur du facteur viii
WO2008115732A2 (en) * 2007-03-20 2008-09-25 Eli Lilly And Company Anti-sclerostin antibodies

Also Published As

Publication number Publication date
MX2010008060A (es) 2010-08-10
CA2712221A1 (en) 2009-07-30
AR070141A1 (es) 2010-03-17
IL207134A0 (en) 2010-12-30
BRPI0905761A2 (pt) 2015-07-14
TW200938630A (en) 2009-09-16
AU2009207340A1 (en) 2009-07-30
EP2245069A1 (en) 2010-11-03
KR20100113589A (ko) 2010-10-21
ZA201005373B (en) 2011-06-29
JP2011510622A (ja) 2011-04-07
EP2245069B1 (en) 2014-06-18
CO6280500A2 (es) 2011-05-20
PE20091351A1 (es) 2009-09-16
US20090232804A1 (en) 2009-09-17
CN101932606A (zh) 2010-12-29
US8236315B2 (en) 2012-08-07
WO2009093138A1 (en) 2009-07-30
AP2010005332A0 (en) 2010-08-31
DK2245069T3 (da) 2014-09-01
CL2009000123A1 (es) 2010-02-05
ES2495092T3 (es) 2014-09-16

Similar Documents

Publication Publication Date Title
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201170716A1 (ru) Антитела к с-мет
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
PH12014502419A1 (en) Specific binding proteins and uses thereof
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
EA201171237A1 (ru) Антитела к dkk-1
EA201201227A1 (ru) Бипаратопные а-бета-связывающие полипептиды
EA201790330A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
EA201991704A2 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201492149A1 (ru) St2-антигенсвязывающие белки
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
EA201070596A1 (ru) Гуманизированные антитела против tl1a
EA201100239A1 (ru) Композиции, одновалетные в отношении связывания cd28, и способы их применения
EA201070553A1 (ru) Антитела к гепцидину и варианты их применения
CY1115349T1 (el) Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου
EA201290589A1 (ru) Cd127-связывающие белки
EA201491452A1 (ru) Антитела к asic1 и их применение
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
EA201590918A1 (ru) Антитела к bmp-6